Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

1
Player Avatar SiouxChief (< 20) Submitted: 8/25/2006 7:28:24 PM : Outperform Start Price: $5.54 NABI Score: -80.16

Drug pipeline is good

Featured Broker Partners


Advertisement